Eli Lilly will pay up to $1.3bn for Superluminal Medicines to discover and progress small-molecule therapeutics for G protein ...

Trump administration demands lower prices in the U.S., forcing the pharmaceutical company to raise them in other markets ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Texas is seeking more than $1 million from Eli Lilly in a lawsuit accusing the drugmaker of persuading physicians to prescribe its medications, including GLP-1s such as Mounjaro and Zepbound, through ...

Eli Lilly has been accused of giving illegal inducements to encourage medical providers in Texas to prescribe its medicines ...

Attorney General Ken Paxton filed a lawsuit this week against Eli Lilly for allegedly bribing Texas health care providers to ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Late last month, President Donald Trump issued letters to Lilly CEO David Ricks and to the CEOs of roughly a dozen other ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, ...

By Nqobile Dludla and Siyanda Mthethwa JOHANNESBURG (Reuters) -Danish drugmaker Novo Nordisk introduced its weight-loss drug ...